PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the “Nasdaq”).
Related Questions
How will the 1-for-10 share consolidation affect BriaCell's liquidity and trading volume on Nasdaq?
What is the expected short‑term price reaction to the reverse split and could it trigger a technical bounce?
Will the consolidation improve BriaCell's ability to raise capital or affect its valuation relative to peers?